Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

domvanalimab (AB154)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Arcus Biosci, Gilead, Otsuka

Drug class:

TIGIT inhibitor

Related drugs:

PD-L1 overexpression	Non Small Cell Lung Cancer	PD-L1 overexpression	Non Small Cell Lung Cancer	zimberelimab + AB154 + AB928 Sensitive: C2 – Inclusion Criteria zimberelimab + AB154 + AB928 Sensitive : C2	zimberelimab + AB154 + AB928 Sensitive: C2 – Inclusion Criteria zimberelimab + AB154 + AB928 Sensitive : C2
PD-L1 overexpression	Non Small Cell Lung Cancer	PD-L1 overexpression	Non Small Cell Lung Cancer	zimberelimab + AB154 Sensitive: C2 – Inclusion Criteria zimberelimab + AB154 Sensitive : C2	zimberelimab + AB154 Sensitive: C2 – Inclusion Criteria zimberelimab + AB154 Sensitive : C2
PD-L1 overexpression	Esophageal Adenocarcinoma	PD-L1 overexpression	Esophageal Adenocarcinoma	zimberelimab + AB154 Sensitive: C3 – Early Trials zimberelimab + AB154 Sensitive : C3	zimberelimab + AB154 Sensitive: C3 – Early Trials zimberelimab + AB154 Sensitive : C3
PD-L1 overexpression	Gastric Cancer	PD-L1 overexpression	Gastric Cancer	zimberelimab + AB154 Sensitive: C3 – Early Trials zimberelimab + AB154 Sensitive : C3	zimberelimab + AB154 Sensitive: C3 – Early Trials zimberelimab + AB154 Sensitive : C3
PD-L1 overexpression	Gastroesophageal Junction Adenocarcinoma	PD-L1 overexpression	Gastroesophageal Junction Adenocarcinoma	zimberelimab + AB154 Sensitive: C3 – Early Trials zimberelimab + AB154 Sensitive : C3	zimberelimab + AB154 Sensitive: C3 – Early Trials zimberelimab + AB154 Sensitive : C3